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Should we treat subclinical hypothyroidism?
Cung B Pham, Allen F Shaughnessy
Subclinical hypothyroidism is a laboratory definition:
a raised concentration of thyroid stimulating hormone
(TSH) yet a normal concentration of free thyroid
hormone, without specific symptoms of thyroid
dysfunction. Patients with subclinical hypothyroidism
have an increased risk of progressing to overt
hypothyroidism. Yet uncertainty exists as to the
benefits of treating such patients.
What is the evidence of the uncertainty?
Recent systematic reviews of cohort studies have
shown a significant increase in coronary heart disease
and cardiovascular related mortality in people with
subclinical hypothyroidism and a TSH concentration
>10mU/l, but nodifference in overallmortality.1 2 The
benefits of treating subclinical hypothyroidism are also
uncertain: although two systematic reviews have
suggested that treatment may decrease total cholesterol
and low density lipoprotein cholesterol levels, particu-
larly in peoplewithTSH concentrations of >10mU/l,3 4
no research has shown a decrease in coronary heart
disease or mortality with treatment.
The Clinical Evidence review reports mixed results
from small randomised controlled trials on the effect of
treatment on symptoms.5 One trial found a significant
increase in anxiety scores but nodifference inquality of
life with treatment.6 A second small randomised
controlled trial found limited evidence of symptom
improvement.7 Patients report that fatigue may
improve with treatment, but quality of life measures
do not change.8 Neuropsychological testing shows no
difference between subclinical hypothyroid and
euthyroid males.9
Two to four per cent of patients with subclinical
hypothyroidism will develop overt hypothyroidism
each year.10 No research has been conducted to show
whether early treatment decreases this progression.
There are risks associated with treatment: about a
fifth of patients diagnosed with subclinical hypothy-
roidism will receive treatment that results in
hyperthyroidism.11 Bone mineral density may be
reduced with treatment, though no research has
shown an increased fracture risk.12 A low TSH
concentration following treatment may be associated
with an increased risk of atrial fibrillation.13
Several organisations have made recommendations
on the screening and treatment of subclinical hypothy-
roidism.TheBritishThyroidAssociation recommends
treatment if TSH concentration is higher than 10mU/l
or if it is lower but the patient has goitre or is trying to
become pregnant.14 The United States Preventive
Services Task Force found insufficient evidence for or
against screening for subclinical hypothyroidism
because of poor evidence that screening leads to
improvement in clinically important outcomes.15
In 2004 a consensus conference published an
evidence based review concluding that general screen-
ing for and treatment of subclinical hypothyroidism
should not be done.16 However, illustrative of the
uncertainty surrounding this topic, a consensus state-
ment from the American Association of Clinical
Endocrinologists, the American Thyroid Association,
and the Endocrine Society emerged from the same
conference to recommend routine screening in adults,
pregnant women, and those contemplating pregnancy
and treatment of most patients with raised TSH
concentrations of 4.5-10 mU/l.17
Is ongoing research likely to provide relevant evidence?
Research registries at the Medical Research Council,
NHS Trusts Clinical Trials Register, the UK Clinical
TrialsGateway, andtheUSNational InstitutesofHealth
do not list current ongoing research on subclinical
hypothyroidism (www.controlled-trials.com/mrct/). A
Cochrane protocol (for a systematic review) is under
way to evaluate the effectiveness of thyroid hormone
therapy for subclinical hypothyroidism (www.
cochrane.org/reviews/en/info_327301022023450202.
html).
What should we do in the light of the uncertainty?
In general, patients should not be routinely screened
for or treated for subclinical hypothyroidism, as the
end point of treatment is not certain, no evidence exists
of long term benefit, and treatment may not be risk-
free. However, mildly raised TSH concentrations
accompanied by vague symptoms such as fatigue or
depressivemoodmay justify a short trialof treatmentas
long as therapeutic goals are clearly outlined with the
patient. If no demonstrable improvement in these
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outcomes occurs, the drug should be discontinued.
Although no guidelines exist on how long to observe
these patients for, a trial of three to six months would
allow time to normalise the patient’s TSH level and
assess for any improvement in symptoms. Patientswho
are discovered to have mildly raised TSH concentra-
tions should be monitored yearly for development of
overt hypothyroidism.
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GUIDELINES
Diagnosis and initial management of acute stroke and
transient ischaemic attack: summary of NICE guidance
Sharon Swain,1 Claire Turner,1 Pippa Tyrrell,2,3 Anthony Rudd,4 on behalf of the Guideline
Development Group
Why read this summary?
In England, stroke is estimated to cost the economy
about £7bn (€8.8bn; $13.9bn) a year. This total
comprises direct costs to the National Health Service
of about £2.8bn, cost of informal care of £2.4bn, and
cost because of lost productivity and disability of
£1.8bn.1 In the United Kingdom, the national sentinel
stroke audits2 3 have shown that over the past 10 years
increasing numbers of patients are being treated in
stroke units, evidence based practice is increasing, and
reductions inmortality and length of hospital stay have
decreased.One of themain aims of the guidance issued
by the National Institute for Health and Clinical
Excellence (NICE) is to ensure that the specialist
treatment and expertise recommended are available to
all patients in England and Wales. This article
summarises key recommendations in the NICE
guideline for the diagnosis and initial management of
acute stroke and transient ischaemic attack.4
Recommendations
NICErecommendationsarebasedonsystematicreviews
of best available evidence. When minimal evidence is
available, recommendations are based on the guideline
development group’s opinion of what constitutes good
practice. Evidence levels for the recommendations are in
the full version of this article on bmj.com.
Rapid symptom recognition and diagnosis
Outside hospital
For people with sudden onset of neurological symp-
toms, use a validated tool such as the face, arm, speech
test (FAST)5 to screen for a diagnosis of stroke or
transient ischaemic attack.
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In hospital
For people who are admitted to an accident and
emergency department with a suspected stroke or
transient ischaemic attack, establish the diagnosis
rapidly using a validated tool such as ROSIER
(Recognition of Stroke in the Emergency Room).6
Brain imaging for suspected transient ischaemic attack
For people who have had a suspected transient
ischaemic attack (that is, whose symptoms and signs
have completely resolved within 24 hours), do the
following:
 Ensure they receive assessment by a specialist and
best medical treatment before reaching a decision
on brain imaging.
 If they are at high risk of stroke (for example, with an
ABCD2 score of ≥4 or with crescendo transient
ischaemic attack) and the vascular territory or
pathology is uncertain, ensure that they have urgent
brain imaging within 24 hours of onset of symptoms.
(The ABCD2 score is a validated tool to assess
subsequent stroke risk in patients with transient
ischaemic attack, based on age, blood pressure,
clinical features (such as unilateral weakness),
presence of diabetes, and symptom duration.)
 If they are at lower risk of stroke (for example, an
ABCD2 score <4) and the vascular territory or
pathology is uncertain, ensure that they have brain
imaging within one week of onset of symptoms).
Brain imaging for all the above patients should
comprise diffusion weighted magnetic resonance
imaging except where contraindicated, in which case
computed tomography should be used.
Brain imaging for early assessment of acute stroke
Perform immediate brain imaging (ideally at the next
scanning slot and definitely within one hour, which-
ever is the soonest) for peoplewith acute stroke if anyof
the following apply:
 Indications for thrombolysis or early anti-
coagulation treatment
 They are receiving anticoagulant treatment
 They have a known bleeding tendency
 They have a depressed level of consciousness
(Glasgow coma score <13)
 They have unexplained progressive or fluctuating
symptoms
 They have papilloedema, neck stiffness, or fever
 They had severe headache at onset of stroke
symptoms.
For all people without indications for immediate
brain imaging, perform scanning as soon as possible
(within amaximumof 24 hours of onset of symptoms).
Urgent carotid endarterectomy and carotid stenting
For those with suspected non-disabling stroke or
transient ischaemic attack, urgent carotid endarterect-
omy or carotid stenting may be appropriate.
 For thosewho are considered candidates for carotid
endarterectomyafter specialist assessment, perform
carotid imaging within one week of onset of
symptoms. For people who present more than one
week after the last symptom of their transient
ischaemic attack has resolved, use the “lower risk”
pathway of management (that is, the same as
for patients at a lower risk of stroke; see full
guideline for recommendations on aspirin
initiation, specialist assessment and intervention,
and measures for secondary prevention).
 For those with stable neurological symptoms and
symptomatic carotid stenosis of 50-99% according
to the criteria of the North American symptomatic
carotid endarterectomy trial (NASCET)7 or 70-99%
according to the criteria of the European Carotid
Surgery Trialists’ (ECST) Collaborative Group8:
- Assess and refer for carotid endarterectomywithin
oneweekofonsetof symptomsof strokeor transient
ischaemic attack
-Provide treatment (carotid endarterectomy)within
a maximum of two weeks of onset of symptoms of
stroke or transient ischaemic attack
- Offer best medical treatment (control of blood
pressure, antiplatelet agents, cholesterol lowering
through diet and drugs, lifestyle advice).
 For those with stable neurological symptoms and
symptomatic carotid stenosis of less than 50%
according to the NASCET criteria or less than 70%
according to the ECST criteria:
- Surgery is not indicated
-Offer best medical treatment (control of blood
pressure, antiplatelet agents, cholesterol lowering
through diet and drugs, lifestyle advice).
Noevidence for early carotid stenting (within the two
week time period covered by the guideline) was
identified. Further research is needed to determine
the safety and efficacy of early carotid stenting
compared with carotid endarterectomy.
Specialist care in acute stroke
After initial assessment either from the community or
from the accident and emergency department, admit
all patients with suspected stroke directly to a specialist
acute stroke unit.
Thrombolysis in people with acute ischaemic stroke
Alteplase (tPA) is recommended for treating acute
ischaemic stroke when used by physicians trained and
experienced in the management of acute stroke. It
should be administered only in a well organised stroke
service and in centres with facilities that enable it to be
used in full accordance with its marketing
authorisation.9 Appropriately trained and supported
staff in accident and emergency departments can
administer alteplase provided that patients can be
managed in an acute stroke service with appropriate
support from neuroradiological staff and a stroke
physician. Protocols should be in place for the delivery
This is one of a series of BMJ
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available evidence; they highlight
important recommendations for
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and management of thrombolysis, including post-
thrombolysis complications.
Aspirin and anticoagulation treatment for acute ischaemic
stroke
 All patients with acute stroke in whom primary
intracerebral haemorrhage has been excluded by
brain imaging should, as soon as possible but
certainly within 24 hours, be given:
- Aspirin 300mg orally if they are not dysphagic, or
- Aspirin 300 mg rectally or by enteral tube if they
are dysphagic.
 Thereafter they should continue taking aspirin
300 mg until two weeks after the onset of the stroke
symptoms, at which time definitive long term
antithrombotic treatment should be started.
Patients being discharged before two weeks can
start on long term treatment earlier.
 Do not use anticoagulation treatment routinely to
treat acute stroke.
Nutrition and hydration in acute stroke
Assessment of swallowing function
 On admission, ensure that an appropriately trained
healthcare professional screens the patient’s
swallowing function before any oral food, fluid,
or medication is offered. If the admission screen
indicates problems with swallowing, provide a
specialist assessment of swallowing, preferably
within 24 hours of admission and not more than
72 hours afterwards
 After specialist assessment of swallowing in patients
with dysphagia, provide food and fluids in a form
that can be swallowed without aspiration.
 Reassess patients with suspected aspiration on
specialist assessment orwho require tube feeding or
dietary modification for three days; consider
instrumental examination (for example, video
fluoroscopy).
Oral nutrition supplementation
 For patients who are unable to take adequate
nutrition and fluids orally:
- Provide tube feedingwith anasogastric tubewithin
24 hours of admission
-Consider a nasal bridle tube or gastrostomy if
patients are unable to tolerate a nasogastric tube
-Refer to an appropriately trained healthcare
professional for detailed nutritional assessment,
individualised advice, and monitoring.
 When screening for malnutrition and the risk of
malnutrition, be aware that dysphagia, poor oral
health, and impaired ability to feed oneself will
affect nutrition.
 Start nutrition support for patients who can swallow
safely and who are at risk of malnutrition. This may
include oral nutritional supplements, specialist
dietary advice, and/or tube feeding.
 Routine nutritional supplementation is not
recommended for patients who are adequately
nourished on admission.
Hydration
 Assess hydration on admission in all patients,
review this regularly, and ensure normal hydration
is maintained.
Early mobilisation and optimum position of patients with
acute stroke
 Mobilise patients as soon as possible (when their
clinical condition permits) as part of an active
management programmeon a specialist strokeunit.
 Help patients to sit up as soon as possible (when
their clinical condition permits).
Overcoming barriers
Arguably two of the main barriers to implementation
are the rapid recognition of symptoms and referral and
timelyaccess tobrain imaging.One factor that is crucial
to ensuring rapid recognition is raising public aware-
ness of stroke and transient ischaemic attack. It is
essential that patients present to healthcare services in
time to receive optimum care. Resources have to be
made available to ensure that patients have access to a
specialist acute stroke team. The provision of brain
imaging represents a huge challenge in improving
stroke service, as currentpracticevarieswidely in terms
of the time delay between presentation and imaging.
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Commentary: Controversies in NICE guidance on acute
stroke and transient ischaemic attack
Helen Rodgers,1,2 Mark Sudlow1,2
The guidelines from the National Institute for Health
and Clinical Excellence (NICE) are a thorough and
helpful summary of evidence in acute management of
stroke and transient ischaemic attack.1 They are a
welcome contribution to increasing understanding of
stroke as a major cause of death and disability and to
improving the structure and funding of services to
tackle the problem.
Controversy is likely to centre on:
 The selective remit for the guidelines given by the
Department of Health
 The conflict between evidence based
recommendations from NICE and recent
statements from the Department of Health and the
Healthcare Commission
 The consensus guidance in areas where evidence is
scant.
Focus on initial management
NICE guidance carries considerable influence over
funding for services. It is therefore worrying that the
Department of Health instructed NICE to examine
only the first few days of treatment for a condition that
often requires prolonged rehabilitation and long term
support. Given fixed resources, an unfortunate con-
sequencemay be the preferential allocation of funds to
the first few days of stroke care and away from other
areas that are also important for the wellbeing of many
who survive stroke—particularly, rehabilitation and
longer term support in returning to andmaintaining an
active life in the community and at work.
Carotid imaging and intervention
The guidelines show a clear application of evidence to
clinical problems, particularly in transient ischaemic
attack. Clinicians will need to be aware of the conflict
between this evidence based guidance (such as the
recommendation that carotid arteries of patients with
transient ischaemic attack should be assessed within a
week and intervention for severe carotid stenosis
performed within a fortnight) and recent standards
from the Healthcare Commission and Department of
Health (that say carotid imaging should be completed
within a day and surgery within two days).2 For most
hospitals, carotid imaging within a week is challenging
but within 24 hours currently impossible and unlikely
to produce additional clinical benefit.
Direct admission to stroke units
Theguidelineshave someconsensus statements that go
beyond the evidence and require structural changes in
services, with potentially detrimental effects on care.
For example, the guidance states that all people with
suspected stroke should be admitted directly to a
specialist acute strokeunit after initial assessment either
from the community or from an accident and
emergency department.1 However, most hospitals
have reconfigured their services so that newly admitted
andunstable patients are cared for in a single area of the
hospital where access by and to medical and nursing
staff is easiest, particularly at night, and so direct
admission to a strokeunitmaymeandeprivingpatients
with stroke of the higher levels of care afforded to other
acute admissions. Strong evidence of effectiveness
would be needed to change policy, but the evidence for
the effectiveness of stroke units in the first few hours
after stroke is limited. Behind the headline recommen-
dation is the later statement that the trials showing
benefits of care in a stroke unit were largely conducted
with admissions to rehabilitation units several days or
weeks after presentation3 and that a trial of direct
admission would be useful.
Although we welcome the guidelines as a useful
summary of current evidence with excellent evidence
based recommendations, wewould caution against the
twindangers of overemphasis on acute treatment to the
exclusion of other aspects and of acceptance of
consensus recommendations that may be detrimental
to care.
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10-MINUTE CONSULTATION
Fungal nail infection
Tim C olde Hartman, Eric van Rijswijk
A 38 year old woman comes to you with a cosmetic
problem in her toenails. She describes her nails as
yellowish brown and crumbly andwith detachment and
thickening of parts of the nails. The problem appeared
gradually, but she is now too embarrassed to wear open
shoes. She wants to know whether it can be treated.
What issues you should cover
Key signs of fungal nail infections—The main changes in
onychomycosis are nail thickening, discoloration, and
onycholysis (separation of the nail plate from the nail
bed).Onycholysis also gives a crumblyaspect to thenail.
Causes and prevalence—In fungal nail infection der-
matophytes invade thenail plate.Theprevalenceof the
infection increases with age. Several studies report a
prevalence of 15-20% in patients aged ≥40 years. In the
general population the prevalence is 3-5%.
Patients requiring extra vigilance—Somepatients (those
with diabetes or poor peripheral circulation) are at risk
of secondary bacterial infections. It is important to
assess the effects and symptoms of the fungal nail
infection in these patients.
Other dermatological problems—Because fungal nail
infections are part of a larger group of dermatomycosis
infections, you should ask about other dermatological
problems. The presence of dermatomycosis elsewhere
on the feet makes the diagnosis of fungal nail infection
more likely. However, psoriasis and lichen planus may
also cause nail problems that look like a fungal infection.
Previous treatments—Patients may already have tried
topical agents bought over the counter. Systemic oral
treatmentsare increasinglybeingadvertised to thepublic.
Is it really a fungal infection?—Yellowish brown nails
and crumbling do not always result from fungal
infections. In only 20-50% of patients with clinically
suspected fungal nail infection is a dermatophyte found
in a culture. Other causes include direct trauma to the
nail (wearing shoes that are too tight; nail biting), poor
peripheral circulation, psoriasis, lichen planus, dia-
betes, or poor foot care.
Effects on quality of life—Fungal nail infections can
have negative effects on the patient’s emotional, social,
andwork life. Sometimes patients complain about pain
or discomfort in walking. They may feel unclean or
ashamed or be fearful of transmitting the infection to
family and other contacts.
What you should do
Examination and diagnosis
Testing for dermatophytes is easy to do in general
practice, although clinical diagnosis of fungal nail
infection is difficult, as dermatophytes are present in
only half of patients. Direct microscopic examination
of small pieces of the nail after they have been soaked
for one hour in 20% potassium hydroxide solution is
needed (false negative rate 30-40%). The validity
depends on the skills of the researcher. Sending nail
and subungual debris for mycological culture testing
increases sensitivity but may take several weeks.
Explanation and reassurance
Tell the patient that although fungal nail infections
sometimes hinder patients’ emotional or social life,
there is no absolute need for treatment. Discuss
possible treatment options with her, including side
effects, success rate of treatment, and recurrence rate
(which is 22% after three years).
Treatments
Topical antifungal treatments—The active antifungal
agent in these preparations is an imidazole, terbinafine,
or a polyene. These drugs are slightly better than
placebo, but treatment often fails because of their
inability to penetrate the entire nail plate.
Systemic antifungal drugs—Itroconazol and terbina-
fine are effective systemic treatments. Continuous
treatment for 3-4 months is successful in 50-80% of
patients. However, side effects—such as headache,
itching, loss of sense of taste, gastrointestinal symp-
toms, rash, fatigue, and abnormal liver function—can
occur. Serious side effects, such as liver failure, are rare.
Cosmetic treatments—Nail filing andnail polish canhelp
to lessen the cosmetic effects of detachment of the nail
plate from the nail bed and thickening of the subungual
region. A chiropodist may also be helpful in mitigating
the effects.
Preventing further infections
Treating tinea pedis prevents the development of fungal
nail infections. As certain public environments such as
communal bathing places, locker rooms, and gymna-
siumscanharbour the infectiousorganisms, patientsmay
benefit from wearing sandals or slippers in these areas.
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